多发性骨髓瘤:揭示不同治疗线的生存数据
Helan Kurian1, Suja Abraham2, Arpith Antony1
1Department of Pharmacy Practice, Nirmala College of Pharmacy, Muvattupuzha, Kerala, India.
Journal of cancer research and therapeutics
|July 20, 2023
概括
在多发性骨髓瘤 (MM) 患者中,一年的坚持性化疗可以使其生存时间超过两年. 较长的无治疗间隔 (TFI) 和时间到下一次治疗 (TTNT) 显著改善整体存活率 (OS) 和无进展存活率 (PFS).
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 多发性骨髓瘤 (MM) 发病率在全球范围内不断增加,近期印度研究显著缺乏.
- 印度MM患者生存率和治疗结果的真实数据很少.
- 了解生存预测因素对于优化MM患者护理至关重要.
研究的目的:
- 分析多发性骨髓瘤患者的生存状况.
- 评估不同治疗方案对MM患者存活率的影响.
- 调查生存结果与诸如无治疗间隔 (TFI) 和时间到下一次治疗 (TTNT) 等参数之间的相关性.
主要方法:
- 对2015-2019年间诊断的MM患者进行了回顾性观察研究.
- 对时间到事件终点的分析,包括TTNT和TFI.
- 累积生存的卡普兰-梅尔估计器和参数分析的卡尔·皮尔森相关性.
主要成果:
- 总生存 (OS) 在82.80%的患者中观察到,平均生存时间为4.02年.
- 在59.80%的患者中,实现了无进展生存 (PFS).
- 无论是OS还是PFS,都与TTNT和TFI (P > 0.05) 显示出显著的正相关性.
结论:
- 一年固定的化疗可以确保超过两年的生存时间.
- 较长的TFI与改善的OS和PFS有关.
- 延长第二线治疗 (LOT) 持续时间与更好的生存状况和PFS相关.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
305
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
9.0K
相关概念视频
Comparing the Survival Analysis of Two or More Groups
226
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
226
Cancer Survival Analysis
390
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
390
Kaplan-Meier Approach
183
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
183
Survival Curves
204
Survival curves are graphical representations that depict the survival experience of a population over time, offering an intuitive way to track the proportion of individuals who remain event-free at each time point. These curves are widely used in fields such as medicine, public health, and reliability engineering to visualize and compare survival probabilities across different groups or conditions.
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
204
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
